Home » Topics » Regulatory » EMA

EMA
RSS

EMA approves compassionate use of OMS-721 in patients with aHUS

April 15, 2015

European orphan drug designation for Trappsol Cyclo transferred to MNE

April 9, 2015

Repros' enclomiphene eligible for new active substance status

April 8, 2015

EMA approves Vectibix for metastatic colorectal cancer expressing wild-type RAS

April 7, 2015

EMA committee recommends approval of Akynzeo

April 1, 2015

EMA committee hands down positive opinion for Lenvima in differentiated thyroid carcinoma

March 31, 2015

CHMP recommends approval of empagliflozin/metformin for type 2 diabetes

March 31, 2015

EMA validates Zinbryta MAA for relapsing forms of MS

March 31, 2015

EMA grants orphan drug designation to Reolysin for gynecological cancers

March 25, 2015

EMA grants orphan status to Kamada treatment for graft-versus-host disease

March 25, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...